Form 4: Aura Biosciences SVP Sells Stock for Tax Obligations

Aura Biosciences' Senior VP of Finance, Amy Elazzouzi, sold 896 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Amy Elazzouzi, Senior Vice President of Finance at Aura Biosciences, Inc. (AURA), reported a transaction on October 29, 2025.
• The transaction involved the sale of 896 shares of Aura Biosciences common stock at a price of $6.35 per share.
• This sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• The sale was automatic and not at the discretion of Ms. Elazzouzi.
• Following this transaction, Ms. Elazzouzi beneficially owns 85,662 shares of common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The sentiment is neutral as this Form 4 reports a routine, non-discretionary sale of shares to cover tax obligations related to RSU vesting, which is a standard practice and does not reflect management's discretionary view on the company's prospects.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

This type of transaction, involving the sale of shares to cover tax obligations upon the vesting of restricted stock units (RSUs), is a common and routine occurrence for executives and employees in publicly traded companies across various industries. It is a standard practice for managing compensation-related tax liabilities.

Comparison to Industry Standards

• The sale of shares to cover tax withholding obligations upon RSU vesting is a standard industry practice for executive compensation, aligning with common equity compensation plans seen in companies like Moderna (MRNA) or Biogen (BIIB) where executives often sell a portion of vested shares to satisfy tax liabilities.
• This transaction is consistent with typical insider reporting requirements for non-discretionary sales under Rule 10b5-1 plans, which are widely adopted across the S&P 500 to allow insiders to sell shares without concerns of insider trading.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.
• Employees: No direct impact mentioned beyond the reporting person's RSU vesting.

Key Dates

Keywords

Aura Biosciences, AURA, Form 4, Insider Transaction, Stock Sale, Tax Withholding, RSU Vesting, Amy Elazzouzi, Corporate Governance